Cadila Healthcare Ltd to Discuss About the Emergency Use Authorization of ZyCov-D Vaccine Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Yes, congrats on the approval. My question pertain to, you have a capacity of 1 crore per month. So if you could indicate the volume of doses in September and October onwards, by what time could we reach 50%, 60% utilization?

Question: Charulata Gaidhani - Dalal & Broacha Stock Broking Pvt Ltd., Research Division - Analyst : Okay. And in terms of profitability, if you could indicate some internal estimates, whether it will be better than the corporate level profitability?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Yes. Have you given any time line when second dose vaccine-related data is to be submitted?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : The 2-dose vaccine data?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. So just -- I think a lot of discussions have already been done on it, that 3 doses vaccine. But just trying to understand like even your competing vaccines have a lesser time duration and dose is obviously the 2-doses vaccine. So apart from marketing, what do you think will incentivize that adolescent or other population to take this vaccine?

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Okay. And second aspect is like cost-wise because we have 3 doses, so what is element we normally discuss with the government while fixing a price? Because for 3 doses, obviously, others have 2 doses. So cost of production of a whole package would be lower for 2-doses vaccine. So can you give some thought on it? REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. AUGUST 23, 2021 / 9:30AM, CADI.NS - Cadila Healthcare Ltd to Discuss About the Emergency Use Authorization of ZyCov-D Vaccine Call

Question: Ranvir Singh - Sunidhi Securities & Finance Ltd., Research Division - Analyst : Yes. So for example, if somebody is taking 2 doses, for example, for INR 400 or INR 500, so their cost of production of the whole package is also lower, you have 3 doses. So the price is likely to be higher than the 2-doses vaccine? This is what I wanted to understand.